Ferring Pharmaceuticals Announces Changes to Board of Directors
1.7.2021 08:30:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors. Jean-Frédéric Paulsen is also appointed to the Board of Directors. All of these changes are effective immediately.
Mr. Paulsen has been Chairman of Ferring’s Board of Directors since 1988. During Mr Paulsen’s tenure, the company has delivered impressive growth and expanded rapidly into new markets, with a presence in almost 60 countries and revenues of nearly EUR 2 billion today.
“My father Frederik Paulsen and stepmother Eva Paulsen founded Ferring in 1950, and it has been an honour to continue their legacy of pioneering science while driving the global expansion of the company,” said Mr Paulsen. “As Ferring enters its next phase of growth, this is the right moment for me to hand over the reins. With his extraordinary track record, I am confident that Lars will effectively guide Ferring towards its ambitious long-term strategic and financial targets, while keeping alive the pioneering spirit on which the company was built.”
Lars Rebien Sørensen has over three decades of general management experience in the pharmaceutical industry and was President and CEO of Novo Nordisk A/S from 2000 until 2016, spearheading the company’s growth into a highly respected and successful global pharmaceutical company. Today, Mr Sørensen is Chair of the Board of the Novo Nordisk Foundation, Chair of the Board of Novo Holdings A/S, a board member of Thermo Fischer Scientific Inc., as well as Chair of the Advisory Board of Axcel Management A/S.
“I’m excited to take on the role of Chairman of the Board of Directors at Ferring Pharmaceuticals and will seek to build on the company’s strong foundations and continue its impressive track record of growth,” said Mr Sørensen. “I look forward to working with the Board of Directors and the Executive Committee, to bring the company’s long-term strategy to life and help more people around the world build families and live better lives.”
Jean-Frédéric Paulsen is Chairman of Ferring Ventures S.A, in addition to other activities. He previously served as Senior Advisor to four Ministers of Economy and Sustainable Development of Georgia and has worked at Mars Inc, Coca-Cola and Credit Suisse.
After he steps down as Chairman, Frederik Paulsen will transition to Honorary Chairman of Ferring’s Board of Directors, continuing to provide support and ensuring a smooth transition for the Board. Mr Paulsen will also dedicate more time to his passions of polar exploration and climate change science, in addition to his diverse philanthropic activities and the oversight of his other investments.
*Refers to the Board of Directors of Ferring Holding S.A - the parent company of the Ferring Pharmaceuticals group
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
# # #
Ferring International Center SA
Ch. de la Vergognausaz, 50
CH-1162 Saint-Prex
Switzerland
www.ferring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005972/en/
Contact information
For more information
Bhavin Vaid
Head of Corporate Communications
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 17:00:00 EET | Press release
For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passion and Perseverance, a new documentary from global technology and data company Experian that explores how access to financial tools, technology and support can help people overcome obstacles and pursue new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105341861/en/ Behind-the-scenes photo from the filming of RECLAIM: Stories of Passion and Perseverance, an Experian documentary. Brody Frye, who received care from The MetroHealth System in Cleveland, Ohio, is featured in the film’s story about healthcare innovation and the p
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 16:32:00 EET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 16:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 16:00:00 EET | Press release
Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation has always been at the forefront of everything we do,” said Jim Huether, CEO of Hyperice. “Heat and dynamic air compressio
European Commission expands license for Alfasigma’s Jyseleca ® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 16:00:00 EET | Press release
The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financial and investor media only. Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Commission (EC) has approved an additional indication to Jyseleca® (filgotinib) 200 mg and 100 mg film-coated tablets, an oral once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. A submission for UK approval has been made to the Medicines and Healthcare products Regulatory Agency (MHRA) and is under review. The European Commission’s approval is based on data that support a favourable benefit-risk profile for filgotinib, including efficacy and safety fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
